Fairvalue-Calculator Fairvalue-Calculator
EN DE

Moberg Pharma AB (MBGPF) Fair Value & Analysis

Healthcare · US · Market cap $51.7M

Price$1.10
Fair Value$5.02
Upside+356.4%
Quality91/100
Evidence: Low Range $3.32 – $6.28

Fair value as of: Jun 25, 2026

Analysis

Moberg Pharma AB (MBGPF) currently trades at $1.10, while our model-based Fair Value estimate is $5.02 — implying the stock looks roughly 356.4% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Moberg Pharma AB (MBGPF) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $5.02 versus a price of $1.10 — about +356% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MBGPF?
Our 21-model fair value for Moberg Pharma AB is $5.02 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.10.
What is the quality score of MBGPF?
Moberg Pharma AB has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.